Literature DB >> 11968011

Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.

Daniel P Zelinski1, Nicole Dodge Zantek, Jennifer Walker-Daniels, Mette A Peters, Elizabeth J Taparowsky, Michael S Kinch.   

Abstract

Estrogen receptor and c-Myc are frequently overexpressed during breast cancer progression but are downregulated in many aggressive forms of the disease. High levels of the EphA2 tyrosine kinase are consistently found in the most aggressive breast cancer cells, and EphA2 overexpression can increase metastatic potential. We demonstrate, herein, that estrogen and Myc negatively regulate EphA2 expression in mammary epithelial cells. These data reveal EphA2 as a downstream target of estrogen and Myc and suggest a mechanism by which estrogen and Myc may regulate breast cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11968011     DOI: 10.1002/jcb.10186

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  24 in total

Review 1.  Differential regulation of EphA2 in normal and malignant cells.

Authors:  Jennifer Walker-Daniels; Angela R Hess; Mary J C Hendrix; Michael S Kinch
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 2.  Eph and ephrin signaling in mammary gland morphogenesis and cancer.

Authors:  Anne-Catherine Andres; Andrew Ziemiecki
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

3.  Regulation of Expression of Hyperalgesic Priming by Estrogen Receptor α in the Rat.

Authors:  Luiz F Ferrari; Dionéia Araldi; Jon D Levine
Journal:  J Pain       Date:  2017-01-09       Impact factor: 5.820

4.  The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.

Authors:  Yan-Yun Zhu; Wen Si; Tie-Feng Ji; Xiao-Qin Guo; Yi Hu; Jun-Lan Yang
Journal:  Tumour Biol       Date:  2015-12-21

Review 5.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

6.  Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.

Authors:  Xiaolin Wang; Haifei Xu; Zhijun Wu; Xiao Chen; Jiandong Wang
Journal:  Int J Exp Pathol       Date:  2017-04-19       Impact factor: 1.925

7.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

Review 8.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

9.  EphA2 up-regulation induced by deoxycholic acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independence.

Authors:  Zhongyou Li; Masamitsu Tanaka; Hideki Kataoka; Ritsuko Nakamura; Ravshanov Sanjar; Kazuya Shinmura; Haruhiko Sugimura
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

10.  EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

Authors:  Aparna A Kamat; Donna Coffey; William M Merritt; Elizabeth Nugent; Diana Urbauer; Yvonne G Lin; Creighton Edwards; Russell Broaddus; Robert L Coleman; Anil K Sood
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.